MedTrace Logo

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug

NCT05362487 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2025-02-26

Study results available
· View outcomes & findings →

Summary

The objective of this non-interventional, observational study is to assess whether changing Chronic Obstructive Pulmonary Disease (COPD) patients from a dry powder inhaler (HandiHaler®) to a soft mist inhaler (Respimat®), without changing the pharmacological compound, will lead to an improvement in Clinical COPD Questionnaire (CCQ) score and in the scores of the three subdomains of CCQ score: symptoms (4 items), functional state (4 items) and mental state (2 items) during a study period of approximately 8 weeks.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Spiriva® Respimat®

Spiriva® Respimat®

DEVICE

Spiriva® HandiHaler®

Spiriva® HandiHaler®

DRUG

Tiotropium bromide

Tiotropium bromide

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2023-01-18
Completion
2023-01-18
FDA Drug
Yes
FDA Device
Yes

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05362487 on ClinicalTrials.gov